Contact us to learn more about

our Premium Content: News alerts, weekly reports and conference planners

DRUG:

Perjeta (pertuzumab)

Contact us to learn more about our Premium Content:

News alerts, weekly reports and conference planners

Company:

Roche

Drug class:

HER2 dimerization inhibitor

Related drugs:

‹

pertuzumab/trastuzumab/hyaluronidase-zzxf (3)

QL1209 (pertuzumab biosimilar) (1)

HS627 (pertuzumab biosimilar) (0)

P013 (pertuzumab biosimilar) (0)

Pertuvia (pertuzumab biosimilar) (0)

pertuzumab/trastuzumab/hyaluronidase-zzxf (3)

QL1209 (pertuzumab biosimilar) (1)

›

HER-2 positive	HER2 Positive Breast Cancer	HER-2 positive	HER2 Positive Breast Cancer	trastuzumab + pertuzumab Sensitive: A1 - Approval trastuzumab + pertuzumab Sensitive : A1	trastuzumab + pertuzumab Sensitive: A1 - Approval trastuzumab + pertuzumab Sensitive : A1
HER-2 positive	Colorectal Cancer	HER-2 positive	Colorectal Cancer	trastuzumab + pertuzumab Sensitive: A1 - Approval trastuzumab + pertuzumab Sensitive : A1	trastuzumab + pertuzumab Sensitive: A1 - Approval trastuzumab + pertuzumab Sensitive : A1
HER-2 amplification	Colorectal Cancer	HER-2 amplification	Colorectal Cancer	trastuzumab + pertuzumab Sensitive: A2 - Guideline trastuzumab + pertuzumab Sensitive : A2	trastuzumab + pertuzumab Sensitive: A2 - Guideline trastuzumab + pertuzumab Sensitive : A2
HR negative	HER2 Positive Breast Cancer	HR negative	HER2 Positive Breast Cancer	trastuzumab + pertuzumab Sensitive: A2 - Guideline trastuzumab + pertuzumab Sensitive : A2	trastuzumab + pertuzumab Sensitive: A2 - Guideline trastuzumab + pertuzumab Sensitive : A2
HER-2 positive	HER2 Positive Breast Cancer	HER-2 positive	HER2 Positive Breast Cancer	pertuzumab Sensitive: A2 - Guideline pertuzumab Sensitive : A2	pertuzumab Sensitive: A2 - Guideline pertuzumab Sensitive : A2
HR positive	HER2 Positive Breast Cancer	HR positive	HER2 Positive Breast Cancer	trastuzumab + pertuzumab Sensitive: A2 - Guideline trastuzumab + pertuzumab Sensitive : A2	trastuzumab + pertuzumab Sensitive: A2 - Guideline trastuzumab + pertuzumab Sensitive : A2
HER-2 positive	Biliary Tract Cancer	HER-2 positive	Biliary Tract Cancer	trastuzumab + pertuzumab Sensitive: A2 - Guideline trastuzumab + pertuzumab Sensitive : A2	trastuzumab + pertuzumab Sensitive: A2 - Guideline trastuzumab + pertuzumab Sensitive : A2
HER-2 amplification + RAS wild-type + BRAF wild-type	Colon Cancer	HER-2 amplification + RAS wild-type + BRAF wild-type	Colon Cancer	trastuzumab + pertuzumab Sensitive: A2 - Guideline trastuzumab + pertuzumab Sensitive : A2	trastuzumab + pertuzumab Sensitive: A2 - Guideline trastuzumab + pertuzumab Sensitive : A2
HER-2 amplification + RAS wild-type + BRAF wild-type	Rectal Cancer	HER-2 amplification + RAS wild-type + BRAF wild-type	Rectal Cancer	trastuzumab + pertuzumab Sensitive: A2 - Guideline trastuzumab + pertuzumab Sensitive : A2	trastuzumab + pertuzumab Sensitive: A2 - Guideline trastuzumab + pertuzumab Sensitive : A2
HER-2 positive	Gastroesophageal Junction Adenocarcinoma	HER-2 positive	Gastroesophageal Junction Adenocarcinoma	trastuzumab + pertuzumab Sensitive: B - Late Trials trastuzumab + pertuzumab Sensitive : B	trastuzumab + pertuzumab Sensitive: B - Late Trials trastuzumab + pertuzumab Sensitive : B
HER-2 positive	Gastric Cancer	HER-2 positive	Gastric Cancer	trastuzumab + pertuzumab Sensitive: B - Late Trials trastuzumab + pertuzumab Sensitive : B	trastuzumab + pertuzumab Sensitive: B - Late Trials trastuzumab + pertuzumab Sensitive : B
HER-2 positive	HER2 Positive Breast Cancer	HER-2 positive	HER2 Positive Breast Cancer	pertuzumab + ado-trastuzumab emtansine Sensitive: B - Late Trials pertuzumab + ado-trastuzumab emtansine Sensitive : B	pertuzumab + ado-trastuzumab emtansine Sensitive: B - Late Trials pertuzumab + ado-trastuzumab emtansine Sensitive : B